Who is sponsoring NCT04001023?

NCT04001023 is sponsored by Turku University Hospital.

What drugs are being tested in NCT04001023?

Interventions in NCT04001023: Imaging with 18F-EF5 PET/CT.

What condition does NCT04001023 study?

NCT04001023 studies Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma, Hypoxia.

Is NCT04001023 still recruiting?

NCT04001023 is currently status unknown. Last updated 7 August 2019.

Last reviewed 2019-08-07 · How we verify

NCT04001023: OVANOX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia

Status unknown NA Last updated 7 August 2019

What this trial tests

NA trial testing Imaging with 18F-EF5 PET/CT in Epithelial Ovarian Cancer in 40 participants. Status unknown.

Timeline

9 March 2017

Primary endpoint
31 December 2022

31 December 2025

Quick facts

Lead sponsor	Turku University Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	9 March 2017
Primary completion	31 December 2022
Estimated completion	31 December 2025
Sites	1 location across Finland

Drugs / interventions tested

Imaging with 18F-EF5 PET/CT

Conditions studied

Epithelial Ovarian Cancer — all drugs for Epithelial Ovarian Cancer →
Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →
Peritoneal Carcinoma — all drugs for Peritoneal Carcinoma →
Hypoxia — all drugs for Hypoxia →

Sponsor

Turku University Hospital

Who can join

Adults 18 to 79, female only, with Epithelial Ovarian Cancer or Fallopian Tube Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this non-randomized prospective study is to use 18F-EF5-PET/CT imaging to identify and locate intraabdominal hypoxic ovarian cancer lesions. With targeted surgical sampling, precisely obtain hypoxic and potentially chemoresistant cancer tissue for our analyses and identify key molecular differences between hypoxic and non-hypoxic tumors within the same patient. A portion of advanced stage EOC are inoperable at diagnosis and can be treated with neoadjuvant chemotherapy (NACT) before surgery. This approach offers a unique opportunity to study how hypoxic tumor areas respond to treatment.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Perspectives on Hypoxia Signaling in Tumor Stroma.
Zhang Y, Coleman M, Brekken RA. · · 2021 · cited 28× · PMID 34202979 · DOI 10.3390/cancers13123070
Synthesis of a 2-nitroimidazole derivative N-(4-[18F]fluorobenzyl)-2-(2-nitro-1H-imidazol-1-yl)-acetamide ([18 F]FBNA) as PET radiotracer for imaging tumor hypoxia.
Nario AP, Woodfield J, Dos Santos SN, Bergman C, et al · · 2022 · cited 8× · PMID 35697954 · DOI 10.1186/s41181-022-00165-0
The feasibility of [18F]EF5-PET/CT to image hypoxia in ovarian tumors: a clinical study.
Laasik M, Hynninen J, Forsback S, Noponen T, et al · · 2020 · cited 7× · PMID 32910291 · DOI 10.1186/s13550-020-00689-z

Verify or expand the search:

Other recruiting trials for Epithelial Ovarian Cancer

Currently open trials in the same condition.

NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07480954 — Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) · Phase 1, PHASE2 · recruiting
NCT07218809 — AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Can · Phase 3 · recruiting
NCT07495397 — Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targete · NA · recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting

Other Turku University Hospital trials

Trials by the same sponsor.

NCT07488494 — Effective Implementation of the Physical Activity and Motor Skills Intervention for 3-6-year-old Children With Cancer (E · NA · not yet recruiting
NCT07316868 — Neuroprotective Effect of Mild Hypothermia Versus Normothermia During Cardiopulmonary Bypass of Coronary Artery Surgery · NA · not yet recruiting
NCT07306000 — Pilot Study: Effects of CCP Intervention on NICU Environment and Preterm Infants Development · NA · recruiting
NCT07272824 — Usability Study of Gestational and Postpartum Weight Management Program · recruiting
NCT07310472 — Administration of the Nasal Influenza Vaccine to Children in Daycare or at a Healthcare Facility · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04001023 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Turku University Hospital
Last refreshed: 7 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04001023.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing